


**FOR IMMEDIATE RELEASE**  
**24<sup>th</sup> May 2007**



## **Amsterdam Molecular Therapeutics Appoints Ferdinand Verdonck as Chairman of the Supervisory Board**

**Amsterdam, the Netherlands, 24<sup>th</sup> May 2007** – Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced the appointment of Ferdinand L. J. Verdonck as chairman of the supervisory board.

Ronald Lorijn, CEO of AMT, said, “We are very pleased to welcome Ferdinand as chairman. With his extensive experience in finance, governance, and strategy, he will provide AMT with valuable guidance in achieving our aim of developing and commercialising our unique suite of products. In the short term, he will support AMT’s senior management team in the successful completion of our recently announced IPO on Euronext Amsterdam.”

Commenting on his appointment, Mr. Verdonck said, “I look forward to working with the AMT team, because of the great potential of the Company’s products to treat rare and orphan diseases, and the professional organization that has been put into place in very little time. The gene therapy field is gathering momentum, and it is particularly interesting to join AMT at this time when its products are entering the clinical development stage and the company is establishing itself as a pivotal participant in this important area of drug development.”

Mr. Verdonck is currently also Director of Easdaq N.V., Galapagos N.V., J.P. Morgan European Investment Trust, Groupe SNEF, Laco Information Services and Phoenix Investment Partners. Most recently Mr Verdonck has served as chairman of Banco Urquijo and director of Dictaphone Corporation.

-Ends-

### **About AMT**

Amsterdam Molecular Therapeutics BV (AMT) is a gene therapy company founded by scientists of the University of Amsterdam Medical Center (AMC) in 1998. AMT focuses on the development of gene-based therapies for orphan diseases. AMT’s technology allows long-term gene expression and the specific delivery of therapeutic genes to target organs or tissues. AMT has optimized and validated the production of AAV-based gene therapy vectors. The result is a unique, stable, and scalable GMP production platform. Its lead product, AMT-011, is in pre-registration trials for the first indication: treatment of complete LPL deficiency. The company’s Management, Supervisory Board and Scientific Advisory Board bring together an extensive know-how of genetics and the biotech and pharmaceutical industries.

**For further information, please contact:**

**AMT:**

André Verwei, CFO

Phone: +31 20 566 7394

Email: [a.verwei@amtbv.com](mailto:a.verwei@amtbv.com)

**Northbank Communications:**

Adam Michael, Account Director

Phone: +44 20 7268 3233

Email: [amt@northbankcommunications.com](mailto:amt@northbankcommunications.com)

**Holly Griffiths**

Account Executive

-----  
Direct line: +44 (0)20 7268 3241

Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102

[www.northbankcommunications.com](http://www.northbankcommunications.com)

Northbank Communications Ltd  
85 Tottenham Court Road,  
London, W1T 4TQ, UK